NEC Corporation
https://www.nec.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From NEC Corporation
Japan's NEC Expands Biopharma Presence With AI-Based R&D
Japanese tech major re-structures its teams for artificial intelligence-based drug development and strategies while expanding its presence in Europe. With confidence in the utility of AI for discovery, it is retaining a key focus on oncology while adding infectious diseases to its targets.
Asia Deal Watch: Juniper Licenses Asia-Pacific-Plus Rights To Kolon’s Osteoarthritis Cell Therapy
Plus deals involving Shionogi/NEC, Ji Xing/LENZ, Kyowa Kirin/Ardelyx, CR Pharma/Everest Medicine and Dr Reddy’s/Novartis.
NEC Moves Beyond IT Tools As It Pursues AI-Driven Drug Discovery Initiative
In an exclusive interview, Japanese tech giant NEC tells Scrip it is aiming for much more than the provision of IT tools in its AI-assisted Drug Discovery Initiative, hoping also to progress assets deriving from cutting-edge technology research.
Xeotron Corp.
Xeotron Corp. employs light activation, digital photolithography, and parallel microfluidics in its biochip making process. The company claims that its flexible platform technology will produce DNA, protein and peptide chips at a faster rate and lower cost than its competitors.
Company Information
- Industry
- Diversified
- Medical Devices
-
Digital Health
- Artificial Intelligence
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice